Toni Choueiri, MD, discusses nivolumab, ipilimumab, and cabozantinib combinations in ongoing phase 3 trials as treatment for patients with advanced renal cell carcinoma.
Toni Choueiri, MD, director of the Lank Center for Genitourinary Oncology and director of the Kidney Cancer Center at Dana-Farber Cancer Institute, discusses nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) combinations in ongoing phase 3 trials as treatment for patients with advanced renal cell carcinoma (RCC).
The ongoing phase 3 COSMIC-313 trial (NCT03937219) is accruing patient with RCC and is examining nivolumab plus ipilimumab as a modern control without sunitinib, compared with a triplet combination of nivolumab, ipilimumab, and cabozantinib, according to Choueiri. This looks at 2 of the 3 drugs which were investigated in the CheckMate 9ER trial (NCT03141177). For CheckMate-9ER, patients with intermediate risk are evaluated for the efficacy of the triplet versus the doublet regimen of nivolumab and cabozantinib.
Another trial currently accruing patients to investigate these drugs is the PDIGREE study (NCT03793166). This study is investigating the combination of the 3 drugs given in a different sequence. Choueiri says it's an academic Alliance-led study that is being conducted in the United States. Patients are given nivolumab plus ipilimumab first, and if they achieve a complete response, they could stop treatment after a year. A patient could be switched to cabozantinib if they have disease progression. The 70% of patients who do not have progressive disease and do not have a complete response will be randomized to nivolumab maintenance, which is what we do normally with nivolumab and ipilimumab or nivolumab and cabozantinib.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More